Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Geraldine O’Sullivan Coyne, Shivaani Kummar, James Hu, Kristen N. Ganjoo, Warren Chow, T. Khanh, Jennifer Zlott, Ashley Bruns, Larry Rubinstein, Jared C. Foster, Lamin Juwara, Robert Meehan, Richard Piekarz, Howard Streicher, Elad Sharon, Naoko Takebe, Andrea Regier Voth, Donald P. Bottaro, Rene Costello, John Wright, James H. Doroshow, Alice P. Chen
Unknown, 2023
Abstract
This research paper explore the methodology and findings associated with Unknown. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
- Multi-targeted tyrosine kinase inhibitors in clinical development:Focus on XL-184 (cabozantinib) 2011
- Novel tyrosine kinase inhibitors for renal cell carcinoma 2013
- [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors]. 2007
- Cabozantinib, a multi-target receptor tyrosine kinase inhibitor, decreases tumor growth and angiogenesis in a patient-derived dedifferentiated liposarcoma xenograft 2014
- Cabozantinib: A Novel Tyrosine Kinase Receptor Inhibitor for the Treatment for Advanced Renal Cell Carcinoma 2017